


PROVIDER NEWSLETTER

A Newsletter for the Molina Healthcare of Illinois (MHIL) Provider Network

Fourth Quarter 2022



In This Issue

“My Health Perks” Program is Live!	1
MCG: Automatic Approval for Advanced Imaging PA	2
New PsychHub Course Available, Offers CEUs.....	2
Q4 Quality Incentive Program for Women’s Health	3
Availity Essentials Portal Tools and Guides	3
Molina SIU Partners with You	4
Balance Billing.....	5
EPSDT Program	5
Medicare Advantage Coming In 2023.....	5
2022–2023 Flu Season	6
Clinical Policy Updates: Highlights from Q3 2022	7
MHIL In the Community.....	8
Biosimilars—What to Watch.....	8
Answers to ECHO Payment Questions.....	9
COVID-19 Treatment Options	10
Partner With Molina In the Community	10

“My Health Perks” Program is Live!

Molina Marketplace members and dependents 18 years and older are eligible for Molina’s health and wellness program called **My Health Perks**. In addition to providing access to a suite of interactive disease-management programs and healthy lifestyle information, all eligible members will have the opportunity to earn a \$50 gift card by completing both of the following activities:

- Complete a preventive wellness examination with their Primary Care Provider.
- Complete the designated Health Risk Assessment via the My Wellness tab on the My Molina Portal (Molina’s member portal).

Members who complete both incentivized activities will be eligible for either a physical or digital gift card of their choosing. Members are permitted to use the gift cards at retailers that accept them.

Please encourage Marketplace members to learn more about the My Health Perks program online via the My Wellness tab on the My Molina Portal. Members can also contact Marketplace Customer Support at **(833) 644-1623** for additional information.

MCG: Automatic Approval for Advanced Imaging PA Requests

Molina Healthcare has partnered with MCG health to offer Cite AutoAuth self-service for advanced imaging Prior Authorization (PA) requests.

What Is Cite AutoAuth and How Does It Work?

By attaching the relevant care guideline content to each PA request and sending it directly to Molina, health care providers receive an expedited, often immediate, response. Through a customized rules engine, Cite AutoAuth compares Molina's specific criteria to the clinical information and attached guideline content to the procedure to determine potential for auto authorization.

Self-services available in the Cite AutoAuth tool include, but are not limited to, MRIs, CTs, and PET scans. To see the full list of imaging codes that require PA, refer to the PA Code LookUp Tool at MolinaHealthcare.com.

How to Access and Learning More

Cite AutoAuth can be accessed via the [Avality Essentials Provider Portal](#) in the Molina Payer Spaces or in the Legacy [Provider Portal](#). It is available 24/7 year-round.

This method of submission (Portal) is strongly encouraged as your primary submission route. However, existing fax/phone/email processes are also available if needed.

Additional information about Cite AutoAuth is available in the Quick Reference Guide on MolinaMarketplace.com. Look on the [Forms & Documents page](#) under the Prior Authorization tab.

New PsychHub Course Available, Offers CEUs

Our PsychHub partners have recently launched their newest online course, Acceptance and Commitment Therapy (ACT) Foundations.

The ACT Foundation's course explores the construct of psychological flexibility.


Learn the action-oriented, empirically based approach to therapy that invites clients to process their feelings while empowering and educating [#mentalhealth](#) practitioners.

Ready To Get Started?

Molina Healthcare network providers can access this and other courses that offer CEUs on the PsychHub platform by clicking this link: app.psychhub.com/signup/molina-mhp

[Go To PsychHub](#)






Acceptance and Commitment Therapy (ACT) Foundations

INTERMEDIATE | 2.00-2.50 CE CREDITS | 2 HRS. 33 MIN

After completing this course, you will be able to:


- Explain the key concepts and six core principles of ACT
- Describe the common barriers for practitioners and clients new to ACT and ways to overcome
- Evaluate how to apply the six core principles and the hexaflex model, using metaphor and exercises in conducting individual ACT therapy sessions



Q4 Quality Incentive Program for Women's Health

2022 CCS BCS Program Scope

Molina offers provider incentives on Cervical Cancer Screenings (CCS) and Breast Cancer Screenings (BCS). CCS measures are directed toward female members aged 21 to 64 years, and include cervical cytology and high-risk human papillomavirus (HPV) testing. BCS measures are for ages 50 to 74 and include mammography.



Providers earn incentives for these screenings **administered from October 1 to December 31, 2022**. Referring providers are eligible to earn **\$500 per qualified member** for Breast Cancer Screenings. Rendering providers are eligible to earn **\$500 per qualified member** for Cervical Cancer Screenings.

It is critical for the provider to use the correct procedural and diagnosis codes when filing the claim in order to receive the incentives. Reference this [2022 CCS BCS Quality Program flier](#) for complete program details, including full

measures and coding guidance located in the [Availity Essentials Provider Portal](#). Payments are in addition to other Molina Incentive Programs.

Leverage These Availity Essentials Portal Tools and Guides

Molina is getting closer to full Availity Essentials Provider Portal functionality. Providers and admin staff can do all this and more online in the Portal:

- [Appeal a claim](#)
- [Correct a claim](#)
- [Request multiple PAs](#)
- [Check status of appeals](#)
- [Smart claims](#)

Learn About Features/Functionalities

Teams from Molina and Availity work closely to launch features and develop tools to help providers learn about them. [MolinaHealthcare.com](#) has recently been updated with some helpful reference materials. Visit the [Frequently Used Forms page](#), and look under the heading [Training & Quick Reference Guides](#).

For assistance using the Availity Portal, call the Availity Help Desk from 7 a.m. to 7 p.m. Central Time at **(800) 282-4548**.

Providers and staff are strongly encouraged to attend live training on the Availity Essentials Portal. Visit Molina's webpage titled [Provider Education Series – Webinars](#), and open the subheading ***NEW*** [Availity Provider Portal](#) for upcoming trainings and registration links. See you there!

Training & Quick Reference Guides

- Availity - How To Open a Support Ticket
- Availity Appeal a Claim
- Availity Checking Appeal Status
- Availity Claim Status Tool Training
- Availity Claims and Smart Claims
- Availity Core Features
- Availity Functionality Roadmap
- Availity Multiple PA Requests
- Availity Smart Claims Training
- Critical Incident Reference Guide
- FQHC Encounter Clinic Billing Quick Reference Guide
- Guide to HFS MEDI Eligibility Search
- Marketplace Providers FAQ
- Marketplace Providers Quick Reference Guide
- Guide to Provider Changes
- Open Enrollment Guide
- Patient Health Resources
- Provider Roster Template Frequently Asked Questions
- Quick Reference Contact Sheet

Molina's SIU Partnering With You to Prevent Fraud, Waste, and Abuse



The National Healthcare Anti-Fraud Association estimates that least 3% of the nation's health care costs—amounting to tens of billions of dollars—is lost to fraud, waste, and abuse. That's money that would otherwise cover legitimate care and services for the neediest in our communities.

To address the issue, federal and state governments have passed a number of laws to improve overall program integrity, including required audits of medical records against billing practices. Molina Healthcare, like

others in our industry, must comply with these laws and proactively ensure that government funds are used appropriately. Molina's Special Investigation Unit (SIU) aims to safeguard Medicare and Medicaid funds—along with Marketplace funds.

You and the SIU

The SIU utilizes state-of-the-art data analytics to proactively review claims to identify statistical outliers within peer (specialty) groups and services/coding categories. Our system employs approximately 1,300 algorithms to identify billing outliers and patterns, over- and underutilization, and other aberrant billing behavior trends. The system pulls information from multiple public data sources and historical databases that are known to identify and track fraud, waste, and abuse. Our system enables us to track provider compliance within correct coding and billing, and the provider contractual agreement.

As a result, providers may receive a notice from the SIU if they have been identified as having outliers that require additional review or by random selection. If your practice receives a notice from the SIU, please cooperate with the notice and any instructions, such as providing requested medical records and other supporting documentation. Contact your Provider Network Manager with questions or email the team at MHILProviderNetworkManagement@MolinaHealthcare.com.

"Molina Healthcare appreciates the partnership it has with providers in caring for the medical needs of our members," explains Scott Campbell, Molina's Associate Vice President overseeing SIU operations. "Together, we share a responsibility to be prudent stewards of government funds. It's a responsibility that we all should take seriously because it plays an important role in protecting programs like Medicare and Medicaid from fraudulent activity."

Molina appreciates your support and understanding of the SIU's important work, and we hope to minimize any inconvenience the SIU audit might cause you and/or your practice.

To report potential fraud, waste, and abuse, contact the Molina AlertLine toll-free at **(866) 606-3889** 24/7 year-round. Plus, use the website to make a report at any time: MolinaHealthcare.Alertline.com.



Balance Billing



Balance billing Molina Healthcare members for covered services is **prohibited**, other than the member's applicable copayment, coinsurance, and deductible amounts. The provider is responsible for verifying eligibility and obtaining approval for those services that require Prior Authorization. Providers agree that under **no circumstance** shall a Molina member be liable to the provider for any sums owed that are the legal obligation of Molina to the provider. Examples of balance billing include:

- Holding members who are dually eligible for Medicaid and Medicare liable for Medicare Part A and B cost sharing.
- Requiring Molina members to pay the difference between the discounted and negotiated fees, and the provider's usual and customary fees.
- Charging Molina members fees for covered services beyond copayments, deductibles, or coinsurance.

Early Periodic Screening, Diagnostic, and Treatment (EPSDT) Program

The Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit provides comprehensive and preventive health care services for children under age 21 who are enrolled in Medicaid. EPSDT is key to ensuring that children and adolescents receive appropriate preventive, dental, mental health, and developmental and specialty services.

Molina Healthcare is required to provide comprehensive services, and furnish all appropriate and medically necessary services needed to correct and ameliorate health conditions, based on certain federal guidelines. EPSDT is made up of screening, diagnostic, and treatment services, and all providers serving members eligible for EPSDT are required to:

- Inform all Medicaid-eligible individuals under age 21 that EPSDT services are available and of the need for age-appropriate immunizations.
- Provide or arrange for the provision of screening services for all children.
- Arrange (directly or through referral) for corrective treatment as determined by child health screenings.



As a provider, it is your responsibility to adhere to and understand EPSDT guidelines and requirements to ensure access to the right care at the right time in the right setting.

Medicare Advantage Coming In 2023

Molina is pleased to offer Medicare Advantage to Illinois residents in certain counties beginning in 2023. For more than 40 years, Molina has provided quality health plans to those who need it most. As our health care partner, we encourage you contract with Molina for all lines of business: Medicaid, MMP/Duals, Marketplace, and now Medicare Advantage.

Are You Contracted For Medicare?

Providers participating in one Molina line of business are not automatically contracted for other lines of business.

Contact your [Provider Network Manager](#) for assistance contracting for Medicaid, MMP, Marketplace, and/or Medicare.

Providers can access key Medicare information on the Member website at MolinaHealthcare.com/members/il. Registering for Molina's [Availty Essentials Provider Portal](#) will give you 24/7 access to important information, make it easy to submit and track claims, and so much more.

Call or email your Provider Network Manager to initiate your Medicare Advantage contract or to learn more about the plan. You can also email the team at MHILProviderNetworkManagement@MolinaHealthcare.com.

2022–2023 Flu Season

The Advisory Committee on Immunization Practices (ACIP) continues to recommend annual influenza vaccinations for everyone who is at least six months of age and older and who does not have contraindications. It's especially important that certain people get vaccinated, either because they are at high risk of having serious flu-related complications or because they live with or care for people at high risk for developing flu-related complications. Additionally, flu vaccinations can reduce the prevalence of flu symptoms that might be similar to and confused with COVID-19.

A licensed, recommended, and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIV4s), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available for the 2022–2023 season.

Important 2022–2023 Updates from the Advisory Committee on Immunization Practices

1. The composition of the 2022–2023 U.S. seasonal influenza vaccines includes updates to the influenza A(H3N2) and influenza B/Victoria components. For the 2022–2023 season, U.S.-licensed influenza vaccines will contain hemagglutinin (HA) derived from an influenza A/Victoria/2570/2019 (H1N1)pdm09-like virus (for egg-based vaccines) or an influenza A/Wisconsin/588/2019 (H1N1)pdm09-like virus (for cell-culture-based and recombinant vaccines); an influenza A/Darwin/9/2021 (H3N2)-like virus (for egg-based vaccines) or an influenza A/Darwin/6/2021 (H3N2)-like virus (for cell-culture-based or recombinant vaccines); an influenza B/Austria/1359417/2021 (Victoria lineage)-like virus; and an influenza B/Phuket/3073/2013 (Yamagata lineage)-like virus.
2. The composition of the 2022–2023 U.S. seasonal influenza vaccines includes updates to the influenza A(H3N2) and influenza B/Victoria components. For the 2022–2023 season, U.S.-licensed influenza vaccines will contain hemagglutinin (HA) derived from an influenza A/Victoria/2570/2019 (H1N1)pdm09-like virus (for egg-based vaccines) or an influenza A/Wisconsin/588/2019 (H1N1)pdm09-like virus (for cell-culture-based and recombinant vaccines); an influenza A/Darwin/9/2021 (H3N2)-like virus (for egg-based vaccines) or an influenza A/Darwin/6/2021 (H3N2)-like virus (for cell-culture-based or recombinant vaccines); an influenza B/Austria/1359417/2021 (Victoria lineage)-like virus; and an influenza B/Phuket/3073/2013 (Yamagata lineage)-like virus.



3. The composition of the 2022–2023 U.S. seasonal influenza vaccines includes updates to the influenza A(H3N2) and influenza B/Victoria components. For the 2022–2023 season, U.S.-licensed influenza vaccines will contain hemagglutinin (HA) derived from an influenza A/Victoria/2570/2019 (H1N1)pdm09-like virus (for egg-based vaccines) or an influenza A/Wisconsin/588/2019 (H1N1)pdm09-like virus (for cell-culture-based and recombinant vaccines); an influenza A/Darwin/9/2021 (H3N2)-like virus (for egg-based vaccines) or an influenza A/Darwin/6/2021 (H3N2)-like virus (for cell-culture-based or recombinant vaccines); an influenza B/Austria/1359417/2021 (Victoria lineage)-like virus; and an influenza B/Phuket/3073/2013 (Yamagata lineage)-like virus.

For a complete copy of the ACIP recommendations and updates, or for information on the flu vaccine options for the 2022–2023 flu season, please visit the Centers for Disease Control and Prevention at [cdc.gov/mmwr/volumes/71/rr/rr7101a1.htm](https://www.cdc.gov/mmwr/volumes/71/rr/rr7101a1.htm).

Molina Healthcare Will Cover the Following Flu Vaccines During The 2022–2023 Flu Season

- Injectable Seasonal Influenza Vaccine (Quadrivalent)—Available from August–April or per state requirements.
- Intranasal Seasonal Influenza Vaccine (FluMist)—Available from August–April or per state requirements.
- Intradermal Influenza Vaccine Quadrivalent (Short Needle) and Flublok—Available from August–April or per state requirements.
- Injectable Seasonal Influenza Vaccine High-Dose—Available from August–April or per state requirements.

Clinical Policy Updates: Highlights from Third Quarter 2022



Molina Clinical Policies (MCPs) are located at [MolinaClinicalPolicy.com](https://www.molinaclinicalpolicy.com). The policies are used by providers, as well as Medical Directors and internal reviewers to make medical necessity determinations. MCPs are reviewed annually and approved

bimonthly by the Molina Clinical Policy Committee (MCPC). The third quarter 2022 updates are noted:

- Epidural Steroid Injections for Back and Neck Pain (previously Epidural Steroid Injections for Chronic Back Pain)
- Radioembolization for Primary and Metastatic Tumors of the Liver
- Spinraza (nusinersen)

The following policies have been retired and are no longer available on the website:

- Abecma (idecabtagene vicleucel)
- Breyanzi (lisocabtagene maraleucel)
- Carvykti (ciltacabtagene autoleucel)
- Intensity Modulated Radiation Therapy (IMRT)
- Kymriah (tisagenlecleucel)
- Lutathera (lutetium Lu 177 dotatate)
- Proton Beam Radiation Therapy
- Proton Beam Therapy for Prostate Cancer

- Provenge (sipuleucel-T)
- Tecartus (brexucabtagene autoleucel)
- Yescarta (axicabtagene ciloleucel)

MHIL In the Community



In early October, Molina Healthcare of Illinois (MHIL) staffers took part in the ribbon-cutting ceremony at the Arrowleaf site in Vienna. Arrowleaf is a nonprofit that works to build well-being for Southern Illinoisans so they can weather life's storms, reach their full potential, and help our communities thrive.

MHIL donated \$8,000 to build **Molina Closets** at Arrowleaf locations in Vienna, Anna, and

Cairo. Molina Closets provide baby-care and other items to community residents free of charge.

Attendees included MHIL Plan President Matt Wolf, State Rep Patrick Windhorst (118th district), Arrowleaf staff and board members, and community residents.



Biosimilars—What To Watch

Biological products are the fastest-growing class of therapeutic products in the United States. Similar to when a generic becomes available, biosimilar and interchangeable products can offer additional options with a potentially lower health care cost.

A biosimilar is a highly similar version of a brand-name biological drug that meets strict controls for structural, pharmaceutical, and clinical consistency. A biosimilar manufacturer must demonstrate that there are no meaningful clinical differences (i.e., safety and efficacy) between the biosimilar and the reference product. Clinical performance is demonstrated through human pharmacokinetic (exposure) and pharmacodynamic (response) studies, an assessment of clinical immunogenicity and, if needed, additional clinical studies. Biosimilars are not considered true generics because, unlike traditional drugs, biologics are not synthetically derived but are derived from organic sources, so there are differences between the reference brand biologic and its biosimilars.


Several bodies of experts have published statements in support for the use of biosimilars and integration into clinical practice guidelines, such as the Crohn's and Colitis Foundation, American College of Rheumatology, and the American Society of Clinical Oncology.

As costs for biological specialty drugs continue to rise, the growing biosimilar market will benefit providers and patients by broadening biological treatment options and expanding access to these medications at lower costs.

An anticipated launch of the first biosimilars for popular drugs such as Humira and Stelara is just around the corner in the first half of 2023. However, it is important to note that while the competition generated by these new launches can help lower health care costs—depending on pricing—biosimilars may not necessarily be the lowest-cost option in all therapeutic categories. Other considerations that may affect the savings potential from a biosimilar launch include the reliability of supply, experience of the manufacturer, and patient or prescriber adoption.

As always, Molina remains committed to continually reevaluating preferred strategies and applying innovative cost-controls to ensure patients receive safe, effective, and quality health care.

This commitment includes potentially creating a preference for biosimilars when value can be added without compromising member satisfaction and safety.




References:

- [fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars](https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars)
- [nccn.org/docs/default-source/clinical/nccn-pharmacy-directors-forum-white-paper-operationalizing-the-safe-and-efficient-use-of-biosimilars.pdf](https://www.nccn.org/docs/default-source/clinical/nccn-pharmacy-directors-forum-white-paper-operationalizing-the-safe-and-efficient-use-of-biosimilars.pdf)
- [rheumatology.org/portals/0/files/biosimilars-position-statement.pdf](https://www.rheumatology.org/portals/0/files/biosimilars-position-statement.pdf)
- [crohnscolitisfoundation.org/sites/default/files/2019-06/biosimilars-statement-needs_0.pdf](https://www.crohnscolitisfoundation.org/sites/default/files/2019-06/biosimilars-statement-needs_0.pdf)

Answers to ECHO Payment Questions

Many of your questions about payments via ECHO are answered [HERE in this provider memo](#). If you don't see the info you need, please visit ECHO's [providerpayments.com](https://www.providerpayments.com) portal or contact ECHO Customer Service at **(800) 895-0621**.



COVID-19 Treatment Options

Four treatment options for COVID-19 are currently available (Paxlovid, Bebtelovimab, Remdesivir, and Molnupiravir) for mild to moderate COVID-19 illness for non-hospitalized people. These options can also lower the chance of progression to severe illness, hospitalization, and death.


The Illinois Department of Public Health (IDPH) continues encouraging providers to assess their patients quickly (within five days of symptom onset) after they have been identified as having COVID-19 to determine if they are eligible for treatment. Prescriptions can be sent directly to IDPH's federal pharmacy partners (Walgreens, Walmart, CVS, Meijer), as well as several community pharmacies listed in this [Treatment Locator](#). **Important note:** Molina's pharmacy partner is CVS.

Please refer to the [NIH Clinical Decision Aid](#), a tool for providers to use as an easy reference guide for treatment.

Note: IDPH does **not** manage allocations for Remdesivir, which is commercially available and cannot be requested through IDPH. Remdesivir is currently the only outpatient treatment option for children under the age of 12 years.

Providers can use these additional resources with patients:

1. For the most up-to-date treatment guidelines, visit [COVID-19 Treatment Guidelines \(nih.gov\)](#).
2. To locate doses of COVID-19 treatments in your area, visit the IDPH Outpatient Therapy locator at [covid-19-therapeutics-locator-dhhs.hub.arcgis.com](#).
 - a. The IDPH Therapy Matchmaker can also be used if you only need a small number of doses: [dph.illinois.gov/covid19/community-guidance/covid19-treatment/matchmaker.html](#).
3. All therapeutics orders are submitted in the U.S. Department of Health and Human Services (HHS) [Health Partner Ordering Portal](#) (HPOP). Existing providers should access their account and choose "create order." New therapeutics providers can submit a registration request to be set up as a provider site by filling out the [New Provider Site Registration Form](#).
4. The information sheet titled [IDPH Paxlovid Providers Checklist](#).
5. If you have questions, contact IDPH at dph.mabtherapy@illinois.gov or call **(800) 889-3931**.



Partner With Molina for Community Outreach



Molina would like to partner with you to help the community. Each month, Molina hosts events throughout the state to distribute food, baby supplies, personal care items, coats, shoes, conduct medical screenings, and so much more.

Providers can help by donating goods, services, or the use of their facilities or parking lots.

Contact Tammy Lackland today at
Tammy.Lackland@MolinaHealthcare.com